Physician profile

Bridget P Smith

Medical · Rochester, NY

NPI 1093368144

$272.89

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$126.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $47.29 2021-2023
Glaxosmithkline, LLC. $45.62 2021
Astrazeneca Pharmaceuticals LP $39.12 2021-2023 Farxiga
Ucb, INC. $33.14 2024 Bimzelx
Genzyme Corporation $29.79 2024
Boston Scientific Corporation $29.63 2023 Watchman Access System
Edwards Lifesciences Corporation $17.02 2021
Janssen Pharmaceuticals, INC $16.17 2021
E.R. Squibb & Sons, L.L.C. $15.11 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bridget P Smith

$272.89

in general payments reported 2019-2025

Years
2021-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/10703308/bridget-p-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.